Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-1439 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| TD-1439 | EXPERIMENTAL | Capsule formulation |
| Placebo | PLACEBO_COMPARATOR | Capsule formulation |
| Name | Type | Description |
|---|---|---|
| TD-1439 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Body Mass Index (BMI) 18 to 32 kg/m2 inclusive * Women of child bearing potential must have a negative pregnancy test and either abstain from sex or use highly effective methods of birth control * Women of non-childbearing potential are at least 2 years postmenopausal or are s...
TD-1439 is an investigational small molecule drug being developed by Theravance Biopharma, Inc. It has been studied in Phase 1 clinical trials in healthy adult and elderly subjects. The specific medical conditions it is intended to treat have not been publicly disclosed.
TD-1439 targets neprilysin (NEP), an enzyme. By acting on this enzyme target, the small molecule is designed to modulate neprilysin activity. Neprilysin is an enzyme involved in the breakdown of certain peptides, and TD-1439 is being developed as an inhibitor of this target.
TD-1439 is being developed by Theravance Biopharma, Inc., which trades on the Nasdaq under the ticker symbol TBPH. The company is the sponsor of the clinical studies conducted for this asset.
TD-1439 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed, and no active trials are currently listed for this asset.
TD-1439 has been evaluated in two completed Phase 1 trials. NCT02903095 was a single ascending dose study in 66 healthy subjects, and NCT02954263 was a multiple ascending dose study in 40 healthy adult and elderly subjects. Both were conducted in the United States.
Both TD-1439 Phase 1 trials were randomized, double-blind, and placebo-controlled studies conducted in healthy volunteers. NCT02903095 tested single ascending doses in 66 subjects, while NCT02954263 tested multiple ascending doses in 40 healthy adult and elderly subjects. Together they enrolled 106 participants.